

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3962330

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
FORERUNNER PHARMA RESEARCH CO., LTD.	06/17/2016
RECEIVING PARTY DATA	
Name:	CHUGAI SEIYAKU KABUSHIKI KAISHA
Street Address:	5-1, UKIMA 5-CHOME, KITA-KU
City:	TOKYO
State/Country:	JAPAN
Postal Code:	115-8543
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	9139647
CORRESPONDENCE DATA	
Fax Number:	(202)293-7860
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-293-7060
Email:	vfletcher@sughrue.com
Correspondent Name:	SUGHRUE MION, PLLC
Address Line 1:	2100 PENNSYLVANIA AVENUE, N.W.
Address Line 2:	SUITE 800
Address Line 4:	WASHINGTON, D.C. 20037
ATTORNEY DOCKET NUMBER:	Q141738
NAME OF SUBMITTER:	VANESSA FLETCHER
SIGNATURE:	/Vanessa Fletcher/
DATE SIGNED:	07/14/2016
Total Attachments: 1	
source=Q141738AssignmentTransferofPatentRightsForerunnerexecuted#page1.tif	

Assignment

Whereas, FORERUNNER PHARMA RESEARCH CO., LTD., Yokohama Bio Industry Center, 1-6 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, JAPAN, hereinafter referred to as the "Assignor," is the owner of a part of the right, title, and interest in and to:

U.S. Patent 9,139,647 entitled "DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-TM4SF20 ANTIBODY," by virtue of an assignment from the inventors thereof recorded on September 9, 2011, at Reel/Frame 026879/0942; and

Whereas, CHUGAI SEIYAKU KABUSHIKI KAISHA, of 5-1, Ukima 5-Chome, Kita-Ku, Tokyo 115-8543, JAPAN (*address*), hereinafter referred to as the "Assignees," desires to acquire Assignor's right, title, and interest in said United States Patent Applications;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

We, the above named Assignor, hereby sell, assign and transfer to the above named Assignee, their successors and assigns, our entire right, title and interest in and to said United States Patent 9,139,647, and we request the Director of the U.S. Patent and Trademark Office to issue any continuing applications, reissue applications and reexamination applications based thereon to the above-named Assignor, its successors and assigns; and we will execute without further consideration all papers deemed necessary by the above named Assignor in connection with United States Patent 9,139,647, when called upon to do so by the above named Assignee.

Date: 17 June 2016

(signature of assignor)/ 

(name of assignor's representative)/ Masami SUZUKI

(title)/ PRESIDENT, FORERUNNER PHARMA RESEARCH CO., LTD.